glp-1 for psoriatic arthritis Big news from the research side of One Rheumatology. Our clinical trial found encouraging improvements in patients with obesity when Taltz® was paired with therapy. This GLP-1 receptor agonists and GIP

Description

The Reality of Muscle Loss on Anti-Obesity Medications: What the Data Actually Shows When you lose 30, 50, or 100 pounds, you are not just losing fatyou are also shedding lean mass

The patient should continue semaglutide while initiating first-line RLS treatment with alpha-2-delta ligands (gabapentin, gabapentin enacarbil, or pregabalin...

From oral formulations to agonist combinations, from muscle preservation to indication expansion, the question remains: who will be the next company to bring a GLP-1-based therapeutic to the market?The 2nd GLP-1-Based Therapeutics Summit is your dedicated platform for leaders and decision-makers to connect, collaborate, and continue to transform healthcare as we know it through the development of GLP-1s.URLs:Tickets: Developer Pricing* - Conference + 2 Workshops : USD 4197.00,Drug Developer Pricing* - Conference + 1 Workshop: USD 3598.00,Drug Developer Pricing* - Conference Only: USD 2999.00,Academic Pricing** - Conference + 2 Workshops: USD 3597.00,Academic Pricing** - Conference + 1 Workshop Only: USD 3098.00,Academic Pricing** - Conference Only: USD 2599.00,Solution Provider Pricing - Conference + 2 Workshops: USD 5097.00,Solution Provider Pricing - Conference + 1 Workshop: USD 4398.00,Solution Provider Pricing - Conference Only: USD 3699.00Speakers: Adam Bell, Vice President, Translational Medicine and Regulatory Affairs, Neuraly, Andrew Young, Chief Scientific and Medical Officer, I2O Therapeutics, Belle van Rosmalen, Director - Incretin Outcomes, Eli Lilly and Co., Damian Bialonczyk, Global Medical Lead - Metabolism, Roche, David Glass, Vice President - Research, Regeneron, Elisa Araldi, Professor, University of Parma, Hong Chen, Director - Search and Evaluation, Novo Nordisk, Jason Mastaitis, Sr